Big news in the fight against neurofibromatosis type 1 (NF1)!

The FDA has just approved mirdametinib (Gomekli) for the treatment of NF1-associated plexiform neurofibromas (NF1-PN) in patients 2 years and older when complete surgical removal isn't possible.

This offers a new hope for many patients and families.

Learn more: http://bit.ly/411tySo

Rare Cancers Program 2025 Coming Soon!

#NF1 #Neurofibromatosis #FDA #Mirdametinib #Gomekli #raredisease